JP2023514567A - 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法 - Google Patents

抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法 Download PDF

Info

Publication number
JP2023514567A
JP2023514567A JP2022548895A JP2022548895A JP2023514567A JP 2023514567 A JP2023514567 A JP 2023514567A JP 2022548895 A JP2022548895 A JP 2022548895A JP 2022548895 A JP2022548895 A JP 2022548895A JP 2023514567 A JP2023514567 A JP 2023514567A
Authority
JP
Japan
Prior art keywords
subjects
ustekinumab
week
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514567A5 (enExample
Inventor
ジョハンズ，ジュエル
リ，キャサリン
マラーノ，コリーン
シュトラウス，リチャード
ジャン，ホンギャン
オブライエン，クリストファー
アデドクン，オモニイ
シールズ‐タトル，キンバリー
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2023514567A publication Critical patent/JP2023514567A/ja
Publication of JP2023514567A5 publication Critical patent/JP2023514567A5/ja
Priority to JP2026019348A priority Critical patent/JP2026097829A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022548895A 2020-02-14 2021-02-12 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法 Pending JP2023514567A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026019348A JP2026097829A (ja) 2020-02-14 2026-02-09 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976582P 2020-02-14 2020-02-14
US62/976,582 2020-02-14
PCT/IB2021/051215 WO2021161270A2 (en) 2020-02-14 2021-02-12 Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026019348A Division JP2026097829A (ja) 2020-02-14 2026-02-09 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法

Publications (2)

Publication Number Publication Date
JP2023514567A true JP2023514567A (ja) 2023-04-06
JP2023514567A5 JP2023514567A5 (enExample) 2025-08-05

Family

ID=77271772

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548895A Pending JP2023514567A (ja) 2020-02-14 2021-02-12 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
JP2026019348A Pending JP2026097829A (ja) 2020-02-14 2026-02-09 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026019348A Pending JP2026097829A (ja) 2020-02-14 2026-02-09 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法

Country Status (11)

Country Link
US (2) US20210253690A1 (enExample)
EP (1) EP4103606A4 (enExample)
JP (2) JP2023514567A (enExample)
KR (1) KR20220141847A (enExample)
CN (1) CN115427444A (enExample)
AU (1) AU2021218265A1 (enExample)
BR (1) BR112022015996A2 (enExample)
CA (1) CA3170677A1 (enExample)
IL (1) IL295545A (enExample)
MX (1) MX2022009987A (enExample)
WO (1) WO2021161270A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024151320A2 (en) * 2022-07-29 2024-07-18 Curium Us Llc [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205276A4 (en) * 2007-09-28 2012-08-15 Janssen Biotech Inc ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
US20170211876A1 (en) * 2014-06-12 2017-07-27 Hoffmann-La Roche Inc. Method for selecting antibodies with modified fcrn interaction
MX2018003376A (es) * 2015-09-17 2018-08-15 Amgen Inc Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
TWI744617B (zh) * 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALIMENT PHARMACOL THER., vol. Vol.48, pp.65-77, JPN6025002748, 2018, ISSN: 0005512690 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. Vol.381, No.13, pp.1201-1214, JPN6025002747, 2019, ISSN: 0005512689 *

Also Published As

Publication number Publication date
BR112022015996A2 (pt) 2022-10-11
EP4103606A2 (en) 2022-12-21
CA3170677A1 (en) 2021-08-19
CN115427444A (zh) 2022-12-02
WO2021161270A2 (en) 2021-08-19
IL295545A (en) 2022-10-01
KR20220141847A (ko) 2022-10-20
EP4103606A4 (en) 2024-04-10
WO2021161270A3 (en) 2021-09-16
MX2022009987A (es) 2022-11-10
WO2021161270A9 (en) 2022-03-24
JP2026097829A (ja) 2026-06-16
US20240002494A1 (en) 2024-01-04
AU2021218265A1 (en) 2022-10-06
US20210253690A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
JP7481423B2 (ja) 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
JP2023052036A5 (enExample)
JP2022500474A5 (enExample)
JP2026031932A (ja) 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
JP2022513094A5 (enExample)
KR20200057072A (ko) 항-il12/il23 항체로 루푸스를 치료하는 안전하고 효과적인 방법
US20240002494A1 (en) Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
US20220112282A1 (en) Method for Treating Crohn's Disease with Anti-IL12/IL23 Antibody
JP2025081391A (ja) 抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法
JP2024541946A (ja) 抗ｉｌ２３特異的抗体を用いてクローン病を治療する方法
KR20230156387A (ko) 항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법
US20240294625A1 (en) Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
JP2025521118A (ja) Ｉｌ２３抗体を用いて乾癬性関節炎を評価及び治療するための方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250627

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251007